Sarbajit Mukherjee, Chief of GI Medical Oncology at Miami Cancer Institute and Co-Chair of GI Clinical Trial Working Group at Hoosier Cancer Research Network, shared a post on LinkedIn about a paper he co-authored with colleagues published in Targeted Oncology:
“Can common cardiovascular drugs influence the way immunotherapy works?
Our new meta-analysis, published in Targeted Oncology, explores the potential interaction between beta-blockers and immune checkpoint inhibitors across solid tumors.
Led by Dr. Kota Tokunaga and Yu Fujiwara, the analysis included over 4,000 patients. While strong preclinical data suggested a possible synergy, current clinical evidence does not show a clear survival benefit. Importantly, toxicity was not increased.
Our ongoing prospective trials will be key to determining whether modulation of the adrenergic pathway can enhance immune response in cancer treatment.
Congratulations to Kota, Yu, and the co-investigators for contributing to this important translational question.”
Title: The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysis
Authors: Kota Tokunaga, Yu Fujiwara, Reo Omori, Takumi Sato, Manmeet Singh Ahluwalia, Sarbajit Mukherjee
You can read the Full Article in Targeted Oncology.
More posts featuring Sarbajit Mukherjee.